Badalona Serveis Assistencials, Badalona, Barcelona, Spain.
J Eval Clin Pract. 2012 Dec;18(6):1170-9. doi: 10.1111/j.1365-2753.2011.01752.x. Epub 2011 Aug 30.
To compare the cost of adding either pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain (PNP).
A retrospective observational study was conducted using medical records from a Spanish health care provider claims database. Patients receiving health care for PNP, above 18 years and for which either pregabalin or gabapentin was initiated between 2006 and 2008 were included. Economic evaluation included health care resource utilization costs and costs due to sick leave.
A total of 1163 patients with PNP were eligible for analysis: 764 were prescribed pregabalin and 399 gabapentin in addition to current pain therapy. Mean age was 59.2 years and 62.2% were female. Concomitant use of analgesics was higher in the gabapentin cohort (3.2 vs. 2.7; P = 0.003), mainly due to non-steroidal anti-inflammatory drugs (74.9% vs. 69.5%; P = 0.018) and opioids (27.7% vs. 17.9%; P = 0.031). Adjusted total costs per patient was lower in pregabalin-treated patients (€2514 vs. €3241; P = 0.003), due to less sick leave (€1067 vs. €1633; P = 0.018) and lower health care costs (€1447 vs. €1609; P = 0.004). The higher acquisition cost of pregabalin (€351 vs. €191; P < 0.001) was largely compensated with lower costs in medical visits, physiotherapy, hospital stays and concomitant analgesics.
In community-treated patients with PNP, total costs were considerably less for those patients initiated with pregabalin therapy than for those patients starting gabapentin add-on therapy. The relatively higher treatment acquisition cost of pregabalin was largely compensated by the overall lower costs for the other components of health care resources and sick leave, thus reducing the economic impact on the health care provider's budget and society.
比较在社区治疗的周围神经病理性疼痛（PNP）患者的管理中添加普瑞巴林或加巴喷丁的成本。
使用西班牙医疗保健提供者索赔数据库中的病历进行回顾性观察性研究。纳入 2006 年至 2008 年间接受 PNP 治疗且开始使用普瑞巴林或加巴喷丁的 18 岁以上患者。经济评估包括医疗资源利用成本和病假费用。
共有 1163 名 PNP 患者符合分析条件：764 名患者除当前疼痛治疗外还开具了普瑞巴林，399 名患者开具了加巴喷丁。平均年龄为 59.2 岁，62.2%为女性。加巴喷丁组同时使用的镇痛药更多（3.2 比 2.7；P = 0.003），主要是因为非甾体抗炎药（74.9%比 69.5%；P = 0.018）和阿片类药物（27.7%比 17.9%；P = 0.031）。普瑞巴林组每位患者的调整后总费用较低（€2514 比 €3241；P = 0.003），这是因为病假时间较短（€1067 比 €1633；P = 0.018）和医疗费用较低（€1447 比 €1609；P = 0.004）。普瑞巴林的较高采购成本（€351 比 €191；P < 0.001）在很大程度上被医疗访问、物理治疗、住院和同时使用的镇痛药的较低成本所抵消。
在社区治疗的 PNP 患者中，与开始加巴喷丁附加治疗的患者相比，开始普瑞巴林治疗的患者的总费用明显较低。普瑞巴林相对较高的治疗采购成本在很大程度上被医疗资源和病假的其他组成部分的总体较低成本所抵消，从而减轻了对医疗保健提供者预算和社会的经济影响。
